Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/jfmpc.jfmpc_1177_21 http://scihub22266oqcxt.onion/10.4103/jfmpc.jfmpc_1177_21 35495846!9051734!35495846     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Family+Med+Prim+Care 2022 ; 11 (3): 1140-1145 Nephropedia Template TP {{tp|p=35495846|t=2022. Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India |pdf=|usr=}}{{35495846}} gab.com Text Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India JO: J Family Med Prim Care http://www.kidney.de/pget.php?&tw=1&pmid=35495846 #FOAvip BACKGROUND: Hydroxychloroquine (HCQ) had generated considerable interest for coronavirus disease 2019 (COVID-19) prophylaxis. We conducted a prospective observational study at a tertiary care hospital in India, with dedicated COVID-19 care facilities. OBJECTIVES: Primary objective was incidence of adverse effects, secondary objective being efficacy in preventing COVID-19. METHODS: Healthcare workers were recruited and grouped based on voluntary HCQ prophylaxis as per national guidelines. Side effects in HCQ group were graded in accordance with national cancer institute-common terminology criteria for adverse events (NCI-CTCAE) version 5.0. At 3-7-week follow-up, groups were compared for COVID-19 exposure, symptoms development and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR results. RESULTS: Among 358 participants recruited, 216 (60.3%) were males and mean age was 31.2 +/- 6.6 years. Chemoprophylaxis was initiated by 258 (72%) participants. After loading dose, 7 (2.7%) reported grade 2 and 1 (0.4%) grade 3 adverse effects. Discontinuation of HCQ due to side effects was reported in 11 (4.3%) participants. Electrocardiogram was done by 50 (19.4%) participants on HCQ; no abnormalities were noted. A total of 106 (41%) among those taking and 63 (63%) among those not taking HCQ were tested for SARS-CoV-2 due to influenza-like illness or significant exposure. Among all participants, 25 (6.9%, 95% confidence interval [CI] 4.3-9.6) developed COVID-19 during the study period. In the group taking HCQ, 10 (3.9%) tested positive compared to 15 (15%) in the group not taking HCQ (P < 0.001). Odds ratio with HCQ intake was 0.34 (95% CI 0.13-0.83, P = 0.01) and the number needed to treat was 12. CONCLUSION: HCQ is safe at the recommended dose for pre-exposure prophylaxis of COVID-19. Twit Text FOAVip Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India ????J Family Med Prim Care http://www.kidney.de/pget.php?&tw=1&pmid=35495846 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35495846 #FOAvip English Wikipedia <ref>{{Cite pmid|35495846}}</ref> Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India #MMPMID35495846 Kadnur HB; Aggarwal A; Soneja M; Singh K; Mittal A; Nischal N; Tirlangi P; Khan AR; Desai D; Gupta A; Kumar A; Jorwal P; Biswas A; Pandey RM; Wig N; Guleria R J Family Med Prim Care 2022[Mar]; 11 (3): 1140-1145 PMID35495846show ga BACKGROUND: Hydroxychloroquine (HCQ) had generated considerable interest for coronavirus disease 2019 (COVID-19) prophylaxis. We conducted a prospective observational study at a tertiary care hospital in India, with dedicated COVID-19 care facilities. OBJECTIVES: Primary objective was incidence of adverse effects, secondary objective being efficacy in preventing COVID-19. METHODS: Healthcare workers were recruited and grouped based on voluntary HCQ prophylaxis as per national guidelines. Side effects in HCQ group were graded in accordance with national cancer institute-common terminology criteria for adverse events (NCI-CTCAE) version 5.0. At 3-7-week follow-up, groups were compared for COVID-19 exposure, symptoms development and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR results. RESULTS: Among 358 participants recruited, 216 (60.3%) were males and mean age was 31.2 +/- 6.6 years. Chemoprophylaxis was initiated by 258 (72%) participants. After loading dose, 7 (2.7%) reported grade 2 and 1 (0.4%) grade 3 adverse effects. Discontinuation of HCQ due to side effects was reported in 11 (4.3%) participants. Electrocardiogram was done by 50 (19.4%) participants on HCQ; no abnormalities were noted. A total of 106 (41%) among those taking and 63 (63%) among those not taking HCQ were tested for SARS-CoV-2 due to influenza-like illness or significant exposure. Among all participants, 25 (6.9%, 95% confidence interval [CI] 4.3-9.6) developed COVID-19 during the study period. In the group taking HCQ, 10 (3.9%) tested positive compared to 15 (15%) in the group not taking HCQ (P < 0.001). Odds ratio with HCQ intake was 0.34 (95% CI 0.13-0.83, P = 0.01) and the number needed to treat was 12. CONCLUSION: HCQ is safe at the recommended dose for pre-exposure prophylaxis of COVID-19. äHydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthc(epmc).pdf DeepDyve Pubget Overpricing